Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
about
Delivering vaccines to the people who need them mostOuter membrane vesicles displaying engineered glycotopes elicit protective antibodiesSynthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogensA model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementationUSA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccineIntact reducing glycan promotes the specific immune response to lacto-N-neotetraose-BSA neoglycoconjugates.Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis BeltA mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.Routinely vaccinating adolescents against meningococcus: targeting transmission & diseaseChicken Anti-Campylobacter Vaccine - Comparison of Various Carriers and Routes of Immunization.The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.Carbohydrates and T cells: a sweet twosome.Vaccine development against Neisseria meningitidis.Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis.Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.A basic dynamic transmission model of Staphylococcus aureus in the US population.T cells control the generation of nanomolar-affinity anti-glycan antibodiesBacterial protein N-glycosylation: new perspectives and applications.The burden and impact of severe and long-term sequelae of meningococcal disease.An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.Carbohydrates as T-cell antigens with implications in health and disease.Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study.Meningococcal carriage in children and young adults in the Philippines: a single group, cross-sectional study.Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.Antibody blocks acquisition of bacterial colonization through agglutination.Meningococcal Group W Disease in Infants and Potential Prevention by Vaccination.Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance.Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries.T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.
P2860
Q28082744-D7B8A340-183A-4DCC-BCF2-9DCF1EF1B223Q28831290-F24FE9FB-FA66-47D8-A28C-7CE4195E2596Q33613913-DE612A70-EED8-4C59-9804-3355D9ADF174Q33714965-02216E28-F5FB-4C1D-AF2B-2F833DE4CCEFQ33754518-5059CC4D-73BF-4EB0-8CBD-8DE22E791611Q34090161-7D6BCE93-3ABA-48E5-94F7-FE1A032725AEQ34113328-665F55C1-E732-461C-823B-1B7BBA54217CQ34450382-0FD087B3-92D4-4483-A25A-00EA6C554A7BQ34593078-8727CC17-A5B1-495E-84E9-4281A2AF2C80Q35188450-148583A8-FD78-4CAF-8322-0BAE9157A45FQ35677495-C445C110-AFBC-44D4-98BD-E993A9A4D6DCQ35766567-BAE85862-FEBA-48E7-9A8B-175538E61E39Q35897201-AEACEE50-154A-4036-A8FE-36D257DC37A3Q36265017-C78EBC2B-93BB-46A4-A234-1D8FFC228A7CQ36351293-D15AA51F-88DF-41BE-B417-DF62DD19C55FQ36486860-07EB5C56-F01D-4EE4-BB8C-FFCE2C3E93B1Q36825737-2B0E026C-4D2D-4158-8493-D6296C9FF4B2Q36915598-60F96C5F-2DDD-46EB-B8FC-F4650993A73EQ37037419-273AB24C-FC6C-46F7-89F4-BF87E56DC2C6Q37112739-CE4ED2B3-F0D0-403C-80AD-879BF4EB2672Q37118132-A6B3CA12-4B0E-422F-B5BF-8406890139DCQ37274707-19660CAE-7E35-47C3-B4F0-897DFA176F19Q37461382-272AF577-C26F-4BA5-BCB0-AB12642A607CQ37524027-A2EFBA51-945A-4B4C-AEF1-464C009457EEQ37561178-4E111798-C597-4BC6-873D-49FA22A588F5Q37730648-023F8752-7C09-42F0-9905-0706DCF76037Q38074949-145F4047-30FD-4D05-965F-9A812C6BE1F1Q38113259-D8BDC741-8E45-4732-B529-FA702B3A560CQ38775024-22EB8C3E-04BE-4285-AAAD-102BD7331A42Q38847198-683189DC-A0B3-4053-BAAF-BF3F0417E47BQ38967874-2AF3560B-E96F-4A08-9BC6-A273AABEAD96Q39365165-B9024FDE-BA9F-4412-AC24-8A4F683BD37AQ40245675-89EC4891-654F-40BF-A8E1-720E422B27E6Q40416064-EC45FC4E-9F3F-44CE-BCA1-F25C20DFEBD4Q41106547-1DFDA5A6-FE22-4B30-8712-0895632378A0Q42209061-66BB9955-508F-401D-BB78-4D7963254AEDQ42361774-740DD7E8-FA32-4880-8B5E-07B2EC3D6AF3Q42937602-9DDF03C1-CEA6-4751-A8BB-27CA937909EFQ46144154-66D3D5C7-465F-4515-B6DE-A4F7AA50F610Q48348733-F9C5EBDB-EEEC-4450-95D0-74C236A9BC72
P2860
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@en
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@nl
type
label
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@en
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@nl
prefLabel
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@en
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@nl
P2093
P50
P1433
P1476
Optimising the use of conjugat ...... and Streptococcus pneumoniae.
@en
P2093
Cynthia G Whitney
E Kim Mulholland
Joachim Hombach
Marie-Paule Kieny
Mary E Ramsay
SAGE subgroup
P304
P356
10.1016/J.VACCINE.2008.05.073
P407
P577
2008-06-17T00:00:00Z